Drug General Information
Drug ID	D0W1SL
Former ID	DNC009127
Drug Name	BUTYLATEDHYDROXYTOLUENE
Drug Type	Small molecular drug
Indication	Discovery agent		Phase 1	[524883]
Structure		Download 2D MOL 3D MOL
Formula	C15H24O
Canonical SMILES	CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C
InChI	1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3
InChIKey	NLZUEZXRPGMBCV-UHFFFAOYSA-N
PubChem Compound ID	31404
Target and Pathway
Target(s)	Carbonic anhydrase II	Target Info	Inhibitor	[529973]
KEGG Pathway	Nitrogen metabolism
	Proximal tubule bicarbonate reclamation
	Collecting duct acid secretion
	Gastric acid secretion
	Pancreatic secretion
	Bile secretion
NetPath Pathway	IL4 Signaling Pathway
	EGFR1 Signaling Pathway
Reactome	Erythrocytes take up carbon dioxide and release oxygen
	Erythrocytes take up oxygen and release carbon dioxide
	Reversible hydration of carbon dioxide
WikiPathways	Reversible Hydration of Carbon Dioxide
	Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes
	Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes
References
Ref 524883	ClinicalTrials.gov (NCT02221375) Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat Soft MistTM Inhaler B in Healthy Male Volunteers. U.S. National Institutes of Health.
Ref 529973	Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. Epub 2009 Feb 4.Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.